Literature DB >> 16004886

Elevated level of plasma homocysteine in patients with slow coronary flow.

Ali Riza Erbay1, Hasan Turhan, Ayse Saatci Yasar, Selime Ayaz, Onur Sahin, Kubilay Senen, Hatice Sasmaz, Ertan Yetkin.   

Abstract

BACKGROUND: Elevated plasma levels of homocysteine are currently considered a major, independent risk factor for cardiovascular diseases. Recently, several investigators have suggested that even mild elevation in plasma homocysteine level can severely disturb vascular endothelial function and subsequently impair coronary blood flow. Accordingly, we investigated plasma homocysteine level in patients with slow coronary flow.
METHOD: Study population included 53 patients with angiographically proven normal coronary arteries and slow coronary flow in all three coronary vessels (group I, 21 females, 32 males, mean age=48+/-9 years), and 50 subjects with angiographically proven normal coronary arteries without associated slow coronary flow (group II, 22 females, 28 males, mean age=50+/-8 years). Coronary flow rates of all patients and control subjects were documented by Thrombolysis In Myocardial Infarction frame count (TIMI frame count). All patients in group I had TIMI frame counts greater than two standard deviations above those of control subjects (group II) and, therefore, were accepted as exhibiting slow coronary flow. The mean TIMI frame count for each patient and control subject was calculated by adding the TIMI frame counts for each major epicardial coronary artery and then dividing the obtained value into 3. Plasma homocysteine level was measured in all patients and control subjects using commercially available homocysteine kits.
RESULTS: There was no statistically significant difference between two groups in respect to age, gender, hypertension, diabetes mellitus, hyperlipidemia and cigarette smoking (p>0.05). Plasma homocysteine level of patients with slow coronary flow were found to be significantly higher than those of control subjects (15.5+/-5.7 vs. 8.7+/-4.2 microM/l, respectively, p<0.001). Moreover, we found a significant positive correlation between plasma homocysteine level and mean TIMI frame count (r=0.660, p<0.001).
CONCLUSION: We have shown that patients with slow coronary flow have raised level of plasma homocysteine compared to control subjects with normal coronary flow. This data suggests that elevated level of plasma homocysteine may play a role in the pathogenesis of slow coronary flow.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16004886     DOI: 10.1016/j.ijcard.2004.05.064

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  16 in total

Review 1.  The coronary slow flow phenomenon: characteristics, mechanisms and implications.

Authors:  Xiao Wang; Shao-Ping Nie
Journal:  Cardiovasc Diagn Ther       Date:  2011-12

2.  Predictive Value of Neutrophil Lymphocyte Ratio and Platelet Lymphocyte Ratio in Patients with Coronary Slow Flow.

Authors:  Mustafa Çetin; Emrullah Kiziltunc; Özgül Uçar Elalmış; Zehra Güven Çetin; Muhammed Bora Demirçelik; Hülya Çiçekçioğlu; Alparslan Kurtul; Selçuk Özkan; Candan Mansuroğlu Avan; Ender Örnek; Feridun Vasfi Ulusoy
Journal:  Acta Cardiol Sin       Date:  2016-05       Impact factor: 2.672

3.  Abnormal nail fold capillaroscopic findings in patients with coronary slow flow phenomenon.

Authors:  Serkan Yuksel; Esra Pancar Yuksel; Mustafa Yenercag; Korhan Soylu; Halit Zengin; Okan Gulel; Murat Meriç; Fatma Aydin; Nilgun Senturk; Mahmut Sahin
Journal:  Int J Clin Exp Med       Date:  2014-04-15

4.  Relationship between carotid artery stiffness and total serum homocysteine in coronary slow flow phenomenon: a high-resolution echo-tracking study.

Authors:  Song Yang; Wen He; Yi Li; Fu-Min Wang; Lu Yin; Li-Juan Du
Journal:  Quant Imaging Med Surg       Date:  2022-05

5.  Elevated levels of sIL-2R, TNF-α and hs-CRP are independent risk factors for post percutaneous coronary intervention coronary slow flow in patients with non-ST segment elevation acute coronary syndrome.

Authors:  Cheng Wang; Yan Wu; Yang Su; Bin Mao; Yihong Luo; Yexiang Yan; Kun Hu; Yi Lu; Wenliang Che; Minying Wan
Journal:  Int J Cardiovasc Imaging       Date:  2022-02-19       Impact factor: 2.357

6.  Early sign of atherosclerosis in slow coronary flow and relationship with angiotensin-converting enzyme I/D polymorphism.

Authors:  Halil Tanriverdi; Harun Evrengul; Hatice Mergen; Ceren Acar; Deniz Seleci; Omur Kuru; Seyhan Tanriverdi; Asuman Kaftan
Journal:  Heart Vessels       Date:  2007-01-26       Impact factor: 2.037

7.  Increased serum resistin levels in patients with coronary slow-flow phenomenon.

Authors:  A Canga; M Cetin; S A Kocaman; M E Durakoğlugil; A Kırbaş; T Erdoğan; A Temiz; A Yılmaz; Y Ciçek
Journal:  Herz       Date:  2013-02-13       Impact factor: 1.443

8.  Hyperhomocysteinemia decreases bone blood flow.

Authors:  Neetu Tyagi; Thomas P Vacek; John T Fleming; Jonathan C Vacek; Suresh C Tyagi
Journal:  Vasc Health Risk Manag       Date:  2011-01-25

9.  Endothelial dysfunction and increased carotid intima-media thickness in the patients with slow coronary flow.

Authors:  Hyun Ju Yoon; Myung Ho Jeong; Sook Hee Cho; Kye Hun Kim; Min Goo Lee; Keun Ho Park; Doo Sun Sim; Nam Sik Yoon; Young Joon Hong; Ju Han Kim; Youngkeun Ahn; Jeong Gwan Cho; Jong Chun Park; Jung Chaee Kang
Journal:  J Korean Med Sci       Date:  2012-05-26       Impact factor: 2.153

10.  Coronary Slow Flow Phenomenon Clinical Findings and Predictors.

Authors:  Hamidreza Sanati; Reza Kiani; Farshad Shakerian; Ata Firouzi; Ali Zahedmehr; Mohammadmehdi Peighambari; Leila Shokrian; Peiman Ashrafi
Journal:  Res Cardiovasc Med       Date:  2016-01-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.